AUSTRALIAN COMMISSION ON SAFETY AND QUALITY IN HEALTH CARE

ECONOMIC EVALUATION OF INVESTIGATOR-INITIATED CLINICAL TRIALS CONDUCTED BY NETWORKS

If the results of 25 high-impact clinical trials were implemented in 65% of the eligible Australian patient populations for one year:

\$1.4 billion in better health outcomes for patients

\$580 million in reduced health service costs



GROSS BENEFIT TO THE AUSTRALIAN ECONOMY

A RETURN OF \$5.80 FOR EVERY \$1 INVESTED IN NETWORK TRIAL RESEARCH

\$1 \$5.80

Trial results only needed to be implemented in 11% of the eligible patient populations for benefits to exceed costs

JUST 9% of the \$2 billion gross benefit from the trials in this study was equivalent to all NHMRC funding received by all Australian networks between 2004 and 2014



A RETURN OF \$51.10 FOR EVERY \$1 AWARDED BY THE NHMRC

TRIALS CONDUCTED BY NETWORKS:

Identify opportunities for better use of resources

Improve safety and quality

Influence clinical guidelines

25 high-impact trials conducted by three Australian clinical trials networks in stroke, intensive care, and maternal and perinatal care were evaluated as part of this study. For more information: www.safetyandquality.gov.au/our-work/clinical-trials/

Australian Clinical Trials Alliance